What is KPV?
A three-letter sequence is a useful starting point, not a complete analytical specification. Confirm stereochemistry, terminal form, salt/counterion, material purity and content basis for the sample. If a study uses KPV inside a carrier, the carrier and release behavior are part of the experimental intervention.
What has mechanism research studied?
Dalmasso and colleagues investigated uptake involving the PepT1 di/tripeptide transporter, alongside NF-κB/MAP-kinase-related inflammatory measurements in epithelial and immune-cell systems and mouse experiments. This supports a transport-and-signaling research question rather than a universal anti-inflammatory claim. [kpv-2008]
Subsequent work examined nanoparticle/hydrogel delivery and later hyaluronic-acid-functionalized carriers. The materials were designed to change access to the experimental target. Delivery-platform findings should remain attached to their tested formulations. [kpv-2010, kpv-2017]
A useful reading sequence is identity → transport → tissue exposure → measured endpoint. Skipping the middle steps can make a formulation result appear to be an intrinsic property of every KPV product.
Bracketed identifiers refer to the papers in the source list below.
Findings worth reading closely
Transporter-linked uptake
The study reported PepT1-mediated uptake and changes in inflammatory signaling and experimental disease measurements.
Keep in view: Cell-line and mouse-model findings do not establish clinical effectiveness or describe all biological settings.
Carrier matters
The engineered preparation changed experimental delivery and inflammatory/histologic measurements compared with the study controls.
Keep in view: The result applies to a delivery system, not automatically to free peptide or a different carrier.
Targeted formulation research
Investigators assessed cell targeting and tissue/inflammatory endpoints with a specialized KPV delivery formulation.
Keep in view: A multicomponent formulation and animal model cannot validate a commercial product bearing the KPV name.
What remains unresolved?
- Which effects reproduce independently across cell types, experimental models and analytical specifications?
- How much of an observed result depends on the peptide, the carrier or the combination?
- What applicable human evidence exists for the precise question being asked? These selected preclinical papers do not answer it.
- No systematic or exhaustive evidence search is claimed here.
Stability, storage & material identity
Carrier-system performance is not a universal storage-stability result. Preserve the distinction between free peptide, dry material, solutions and engineered formulations.
Follow documentation for the exact material and packaging; no general shelf life or solution-use period is established in this reference.
For research use only. No administration or formulation-preparation instructions are supplied.
Check product-specific storage documentation →
Questions, answered.
What does KPV stand for?
It denotes the amino-acid sequence lysine–proline–valine. A full laboratory specification still needs structural and analytical detail.
Why do KPV delivery studies need separate interpretation?
Nanoparticles, hydrogel composition and targeting modifications are part of the tested preparation. Their results cannot automatically be assigned to unformulated KPV.
Are these human colitis trials?
No. The selected papers combine cell systems with animal colitis models. Human-derived cells are not clinical trial participants.
Sources & reading notes
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation · Dalmasso G et al. (2008)Source access: abstract.
- Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model · Laroui H et al. (2010)Source access: abstract.
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis · Xiao B et al. (2017)Source access: abstract.
Primary abstracts and metadata checked November 1, 2026. Findings are explicitly preclinical and formulation-specific. No complete clinical review or independent scientific review is claimed.